CRISPR Therapeutics Future Growth
Future criteria checks 2/6
CRISPR Therapeutics is forecast to grow earnings and revenue by 37.6% and 37.6% per annum respectively. EPS is expected to grow by 37.5% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
37.6%
Earnings growth rate
37.5%
EPS growth rate
Biotechs earnings growth | 25.8% |
Revenue growth rate | 37.6% |
Future return on equity | 9.5% |
Analyst coverage | Good |
Last updated | 18 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 930 | -180 | -234 | -31 | 14 |
12/31/2025 | 404 | -381 | -314 | -261 | 23 |
12/31/2024 | 121 | -454 | -284 | -186 | 26 |
12/31/2023 | 371 | -154 | -272 | -260 | N/A |
9/30/2023 | 170 | -354 | -295 | -278 | N/A |
6/30/2023 | 170 | -416 | -363 | -343 | N/A |
3/31/2023 | 100 | -524 | -377 | -352 | N/A |
12/31/2022 | 1 | -650 | -533 | -496 | N/A |
9/30/2022 | 14 | -681 | -509 | -468 | N/A |
6/30/2022 | 15 | -633 | -516 | -445 | N/A |
3/31/2022 | 915 | 312 | 414 | 504 | N/A |
12/31/2021 | 915 | 378 | 457 | 539 | N/A |
9/30/2021 | 902 | 412 | 465 | 544 | N/A |
6/30/2021 | 902 | 447 | 502 | 549 | N/A |
3/31/2021 | 1 | -392 | -309 | -287 | N/A |
12/31/2020 | 1 | -349 | -257 | -238 | N/A |
9/30/2020 | 77 | -211 | -167 | -154 | N/A |
6/30/2020 | 289 | 20 | 45 | 55 | N/A |
3/31/2020 | 289 | 46 | 40 | 48 | N/A |
12/31/2019 | 290 | 67 | 50 | 57 | N/A |
9/30/2019 | 213 | -11 | 18 | 25 | N/A |
6/30/2019 | 1 | -200 | -133 | -128 | N/A |
3/31/2019 | 2 | -185 | -121 | -117 | N/A |
12/31/2018 | 3 | -165 | -99 | -96 | N/A |
9/30/2018 | 35 | -117 | -85 | -83 | N/A |
6/30/2018 | 37 | -91 | -83 | -79 | N/A |
3/31/2018 | 40 | -75 | -74 | -69 | N/A |
12/31/2017 | 41 | -68 | -78 | -70 | N/A |
9/30/2017 | 11 | -51 | N/A | -75 | N/A |
6/30/2017 | 10 | -41 | N/A | -71 | N/A |
3/31/2017 | 7 | -36 | N/A | -69 | N/A |
12/31/2016 | 5 | -23 | N/A | -53 | N/A |
9/30/2016 | 3 | -53 | N/A | 33 | N/A |
6/30/2016 | 2 | -44 | N/A | 40 | N/A |
3/31/2016 | 1 | -31 | N/A | 51 | N/A |
12/31/2015 | 0 | -26 | N/A | 59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C2RS34 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: C2RS34 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: C2RS34 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: C2RS34's revenue (37.6% per year) is forecast to grow faster than the BR market (7.2% per year).
High Growth Revenue: C2RS34's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: C2RS34's Return on Equity is forecast to be low in 3 years time (9.5%).